Ventyx Biosciences (NASDAQ:VTYX) Shares Gap Up to $13.96

Ventyx Biosciences, Inc. (NASDAQ:VTYXGet Rating)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $13.96, but opened at $14.40. Ventyx Biosciences shares last traded at $15.18, with a volume of 496 shares trading hands.

Several analysts have issued reports on the company. Zacks Investment Research upgraded Ventyx Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, March 26th. Canaccord Genuity Group initiated coverage on Ventyx Biosciences in a report on Thursday, March 31st. They set a “buy” rating and a $30.00 price target for the company. Oppenheimer initiated coverage on Ventyx Biosciences in a report on Tuesday, February 1st. They set an “outperform” rating and a $30.00 price target for the company. Finally, Canaccord Genuity Group initiated coverage on Ventyx Biosciences in a report on Thursday, March 31st. They set a “buy” rating for the company. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $38.00.

The stock’s fifty day moving average price is $12.18.

A number of hedge funds have recently bought and sold shares of the business. venBio Partners LLC acquired a new stake in Ventyx Biosciences in the 4th quarter valued at about $99,529,000. Third Point LLC acquired a new stake in Ventyx Biosciences in the 4th quarter valued at about $83,083,000. Citadel Advisors LLC acquired a new stake in Ventyx Biosciences in the 4th quarter valued at about $74,736,000. BlackRock Inc. acquired a new stake in Ventyx Biosciences in the 4th quarter valued at about $9,826,000. Finally, American Century Companies Inc. acquired a new stake in Ventyx Biosciences in the 4th quarter valued at about $7,800,000. 60.05% of the stock is currently owned by institutional investors.

Ventyx Biosciences Company Profile (NASDAQ:VTYX)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus.

Featured Stories

Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.